Abbott Laboratories (ABT): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Abbott Laboratories ( ABT) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.2%. By the end of trading, Abbott Laboratories rose 34 cents (1%) to $33.84 on average volume. Throughout the day, 12.5 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 14.8 million shares. The stock ranged in a price between $33.65-$33.99 after having opened the day at $33.65 as compared to the previous trading day's close of $33.50. Other companies within the Health Care sector that increased today were: Opexa Therapeutics ( OPXA), up 160.3%, Protalix BioTherapeutics ( PLX), up 14.7%, ImmunoCellular Therapeutics ( IMUC), up 12.4%, and EntreMed ( ENMD), up 12.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $53.54 billion and is part of the drugs industry. The company has a P/E ratio of 6.7, below the S&P 500 P/E ratio of 17.7. Shares are up 3.4% year to date as of the close of trading on Monday. Currently there are eight analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Alibaba, Qorvo, Abbott Laboratories, Square: 'Mad Money' Lightning Round

Walmart Is One of 63 Companies Contributing Massively to Aid Harvey Relief

Abbott Updates Pacemaker, Defibrillator Software to Protect Against Hacking